Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urologic Neoplasms × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 6 Breast Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Squamous Cell 4 Stomach Neoplasms 2 Prostatic Neoplasms 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Adenocarcinoma of Lung 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Cancers of the Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Pathologic Complete Response 1 PFS 1 NSCLC Harboring NRG1 Fusion 1 Multiple Myeloma 1 Lymphoma 1 Gallbladder Neoplasms 1 Focus of Study Instead 1

Interventions

Gemcitabine 5 Trastuzumab 3 pembrolizumab 2 Pemetrexed 2 Paclitaxel 2 Carboplatin 2 vinflunine 1 niraparib 1 montanide ISA 51 1 flt3 ligand protein 1 enfortumab vedotin 1 cabozantinib 1 atezolizumab 1 abemaciclib 1 Zoledronic Acid 1 Urinary Diversion 1 Therapeutics 1 Thalidomide 1 Sunitinib 1 Radiosurgery 1 MART-1 Antigen 1 Immunoglobulins, Intravenous 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Dosage Forms 1 Cystectomy 1 Cisplatin 1 Cetuximab 1 CP protocol 1 Biological Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡